Category: Drugs

Some Pharmacies Charge More than Allowed

The Washington Post ran an article about a Medicare Part D drug plan enrollee. Her late father had been a pharmacist and owned a small drugstore while she was growing up. She thought it would be neat to patronize a small, independent drugstore to refill a prescription – and she found one in her preferred pharmacy network.  A 90-day prescription refill that should have cost her a $3 co-pay turned out to be $58. Whoa; what’s the deal she inquired?  On this particular prescription, the drugstore stood to lose some money so it claimed. Or, maybe its profit margin wasn’t as high as it thought it should be. It asked its customer to willingly throw in an extra $55 towards the cost of the prescription to pad its bottom line.  Of course, this violated the contract the drugstore had signed with the Medicare Part D plan.

As the article explained, when drug plans negotiate with drugstores, they often drive a hard bargain. But the carrot they dangle to drugstores is a lot of increased business. Profits per script may be low; but the number of scripts is far higher. While in the drugstore, there’s a good chance the patron will pick up a bottle of aspirin, maybe some bandages.

The author said many of the smaller drugstores claim they cannot make any money on the low reimbursements (known and maximum allowable cost) that drug plans pay. But they also aren’t willing to forgo all the potential customers, so they hope you don’t notice the prices are higher than what they agreed to in their contract. Basically, the store gets reimbursed its contractual amount and charges a co-pay far more than the customer was supposed to pay.

The author left without her prescription, which she bought elsewhere. The moral of the story: be on the lookout for price gouging. It may not be part of the contract, but some stores will try to charge higher prices rather than sell a particular drug cheaper than they feel it’s worth.

Oh by the way, lawmakers in Oklahoma are trying to make it easier for drugstores to engage in this behavior even if it violates their contract terms. Read my Health Alert, These Politicians Must be on Drugs (or Maybe They Should Be).

Drug Expenditures Rise

By David Sobczak

The US Health and Human Services Department published a recent report finding that prescription drug spending increases are being fueled by rising prices and a transition toward pricier medications. In fact, drug spending increased 12.6 percent from 2013 to 2014 alone, and it is projected to increase from $424 billion to $457 billion from 2014 to 2015.  Drug spending is expected to continue outpacing overall health care spending through 2018.

What is driving the drug spending increases? According to the aforementioned report, the total number of prescriptions went up 11 percent between 2010 and 2014, a jump the report attributes to increased prescriptions per prescribed individual along with overall population increases.  Furthermore, the report suggests that, because overall spending grew faster than the number of prescriptions, higher prices may be responsible for the spending hikes.  In fact, from 2010 to 2014, prescription drug spending climbed from $356 billion to $424 billion, a growth rate of 26 percent.

DrugSpending

 

 

Ten Percent of Cancer Drug Spending Wasted

BMJA remarkable study published in the BMJ concludes that $1.8 billion of the $18 billion spent on the 20 most expensive cancer drugs in the U.S. is wasted due to cunning marketing by drug-makers. Chemotherapeutic doses are often adjusted by body weight. However, the drugs are shipped in vials containing doses appropriate to bigger people. Once opened, the drug that remains after an oncologist selects the does appropriate for a smaller or average-sized person has to be discarded.

vaccine-shot

The authors allege the drug-makers do this deliberately, to increase profits. Their proposed solution is that the Food and Drug Administration should regulate the size of vials!

There is a better way.

First, the FDA is not concerned with the cost of medicines. The proposed solution has nothing to do with safety or efficacy, so is not within the FDA’s purview.

Read More » »

Can’t Afford the Cost of that Fancy New Drug? MIT Says Get a Mortgage

Writing in the journal Science Translational Medicine, MIT researchers discuss a novel way for patients to afford breakthrough medications they otherwise could not afford. Their interim solution: health care loans.  Not unlike the way most people buy a house, a health care loan would turn a large upfront medical bill into a series of manageable periodic payments. In my opinion, a better analogy is a car loan. If you’re diagnosed with cancer or are at risk of losing your liver to hepatitis C, taking out a $30,000 loan to pay for treatment beats the alternative.

Read More » »

Will Drug Companies’ Price Firewall Melt?

Variety of Medicine in Pill BottlesA recent Kaiser Family Foundation Tracking Poll brings dire news for innovative drug companies: 83 percent of respondents favor a policy “allowing the federal government to negotiate drug prices for Medicare beneficiaries.” That includes 93 percent of Democrats and 74 percent of Republicans.

Despite dramatic headlines about pharmaceutical price increases, they have been in line with price increases for other health goods and services. Medicare payments to doctors and hospitals have been negotiated by government for over half a century, without containing costs.

Nevertheless, we are at a point in the polls where any careerist politician, Democrat or Republican, will likely follow Hillary Clinton’s lead demanding politically fixed drug prices. This teaches a lesson about inviting the government into your business.

Read More » »

Good News for the Consumer: FDA is Approving More Generic Drugs

The sharp rise in the price of some generic drugs is finally slowing according to drug channel expert, Adam Fein.   In theory, generic drugs face unlimited competition. But the reality is often much different. There are a variety of reasons generic drug prices can climb, including consolidation in the supply chain as well as legal and regulatory reasons that allow drug makers to jack prices up.

The FDA has the power to solve some of these problems. But when it gets bogged down and cannot quickly process applications for new abbreviated new drug applications (ANDAs) fast enough, the opportunity exists for prices to skyrocket. Consider the case of former Turing Pharmaceutical CEO Martin Shkreli.  Shkreli bought the rights to a little-used, 60-year old drug called Daraprim for $55 million.  Why would Turing Pharmaceutical even want a generic drug that only had a sliver of a market? Because there was only one supplier. Turing could invest $55 million and potentially jack up the price and gouge insurance companies. If Turing was the only supplier it could raise the price from $13.50 to $750, which it did. That $55 million investment could potentially earn $200 million a year for a few years until the FDA could approve a competitor’s drug.  That was not likely to happen for several years.

The FDA has sped up its pace by hiring nearly 1,000 new employees. Over the past few years, the agency approved about 400 to 500 generic drugs a year (35 to 45 drugs a month). Yet, since April 2015, it has been approving or tentatively approving 60 to 70 drugs a month. In December 2015 (a short month) it approved nearly 100. That’s good news for consumers. Research shows that the price of a generic drug has an inverse correlation with the number of competitors making the same generic drug.

Uninsured Shoppers May Lose their Drug Discounts Unless they Find a New Card

Walmart is known as the retailer that began the $4 generic prescription program. It became the go-to store for cheap generics if you didn’t have prescription drug coverage. Other major retailers soon followed. It was a game changer in the pharmacy business. Generic drugs that were once a lucrative business for pharmacies were suddenly low-margin products. Of course, not every generic is $4, but the $4 list is pretty robust.  For those prescriptions that are not on the $4 list, patrons often turn to a discount pharmacy card program, such as PS Card or GoodRx.  A pharmacy discount card is a service where uninsured individuals (and anyone who wants one) join a network that has partnered with a pharmacy benefit manager (PBM).  PBMs administer drug plans for insurers, health plans and government programs such as Medicare and Medicaid. Because PBMs are volume purchasers of drugs, they’ve negotiated a better price than is typical for walk-in customers. For example, let’s assume you join a discount drug plan whose PBM partner also administers the drug plan for General Motors. GM pays lower prices for drugs than one consumer paying cash.  Yet, card-holding cash-paying customers benefit from the volume discounts that huge purchasers receive.

Read More » »

Reciprocal Regulatory Approval To Reduce Drug Prices

prescription-drug-shortageSenators Ted Cruz (R-TX) and Mike Lee (R-UT) recently introduced the RESULT Act, which would allow drugs and medical devices approved in certain other countries to be allowed in the U.S. as well. The countries included are European Union members, Israel, Canada, Japan, and Australia.

The benefits of this act would be significant. Professor Daniel Klein of the Mercatus Institute at George Mason University and Professor William L. Davis of the University of Tennessee at Martin have surveyed economists on this policy, and a majority agree it would improve patients’ access to safe and effective drugs.

Read More » »

Why Are U.S. Prescription Prices Higher?

Variety of Medicine in Pill BottlesJeanne Whalen of the Wall Street Journal has written a feature article comparing U.S. prescription drug prices to those overseas. Unsurprisingly, she find prices in other developed countries lower, and credits government price controls in other countries with (pretty much) all the difference.

A vial of the cancer drug Rituxan cost Norway’s taxpayer-funded health system $1,527 in the third quarter of 2015, while the U.S. Medicare program paid $3,678. An injection of the asthma drug Xolair cost Norway $463, which was 46% less than Medicare paid for it.

Drug prices in the U.S. are shrouded in mystery, obscured by confidential rebates, multiple middlemen and the strict guarding of trade secrets.

The state-run health systems in Norway and many other developed countries drive hard bargains with drug companies: setting price caps, demanding proof of new drugs’ value in comparison to existing ones and sometimes refusing to cover medicines they doubt are worth the cost.

(Jeanne Whalen, “Why the U.S. Pays More Than Other Countries for Drugs,” Wall Street Journal, December 1, 2015)

I do not dispute the facts of the article, but the article’s misidentifying the primary reason why drug prices are different. It actually does a good job of differentiating countries where the state exercises monopsony power over drug purchases (like Norway) and those where the state does not exercise purchasing power, but imposes price controls on al sales (like Canada). It is easy and intuitive to conclude that such government interventions reduce prices. However, contrary evidence shakes that thesis. Relative purchasing power better explains the difference.

Read More » »